Core Insights - Y-mAbs Therapeutics, Inc. is set to report its first quarter 2025 results on May 13, 2025, before market opening [1] - A conference call and webcast will be held on the same day at 8:00 a.m. ET to discuss the results, with a live audio webcast available on the company's Investor Relations website [2] Company Overview - Y-mAbs is a commercial-stage biopharmaceutical company focused on developing and commercializing novel radioimmunotherapy and antibody-based therapeutic products for cancer treatment [3] - The company utilizes advanced technologies such as the Self-Assembly DisAssembly (SADA) Pretargeted Radioimmunotherapy Platform (PRIT) and bispecific antibodies from the Y-BiClone platform [3] - Y-mAbs has a broad product pipeline, including DANYELZA® (naxitamab-gqgk), which is the first FDA-approved treatment for relapsed or refractory high-risk neuroblastoma in specific patient conditions [3]

Châtillon, France, May 5, 2025 DBV Technologies to Participate in the Citizens JMP Life Sciences Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced Daniel Tassé, Chief Executive Officer, will participate in a fireside chat at the Citizens JMP Life Sciences Conference on Wednesday, May 7, 2025, at 11:00am ET, in New York, NY. A live webcast of the fireside chat can be accessed here, and will also be availab ...

OSE Immunotherapeutics Announces >90% of Responders Maintained Symptomatic Remission Through Extension Period on Lusvertikimab Lusvertikimab well tolerated over the 24-week additional treatment period.Oral presentation at DDW 2025 of clinical data from the anti-IL-7R mAb Lusvertikimab open-label extension of the phase 2 CoTikiS study in ulcerative colitis.1,2Full clinical data package for study demonstrates potential of a first-in-class monotherapy with a novel mechanism of action in chronic and inflammator ...

May 5th, 2025 1st Quarter 2025 Financial Results & Corporate Update This Slide Presentation Includes Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: BioNTech's expected revenues and net profit/(loss) related to sales of BioNTech's COVID-19 vaccine, referred to as COMIRNATY where approved for use under full or conditional marketing auth ...

BioNTech (BNTX) Q1 2025 Earnings Call May 05, 2025 08:00 AM ET Speaker0 Welcome to BioNTech's First Quarter twenty twenty five Earnings Call. I would like to hand the call over to Michael Horowitz, Director of Investor Relations. Please go ahead. Speaker1 Thank you. Good morning and good afternoon. Thank you for joining BioNTech's First Quarter twenty twenty five Earnings Call. As a reminder, the slides we will be using during this call and the corresponding press release we issued this morning can be found ...

Phase 1b/2a trial designed to evaluate the safety and feasibility of IFx-Hu2.0 in combination with Keytruda® when administered via Interventional Radiology (IR) in patients with deep- seated tumors without associated cutaneous tumorsTAMPA, Fla., May 5, 2025 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today announced the initiation of its Phase 1b/2a trial of ...

Summit Therapeutics (SMMT) Q1 2025 Earnings Call May 01, 2025 04:30 PM ET Speaker0 Thank you for standing by. Hello, and welcome to the Summit Therapeutics Q1 twenty twenty five Earnings Conference Call. I would now like to turn the call over to our Chief Business and Strategy Officer, Dave Van Carrs. Please go ahead, sir. Speaker1 Good afternoon, and thank you for joining us. A press release was issued earlier this afternoon and is available on the homepage of our website. Our Form 10 Q was also filed and ...

Core Insights - Bolt Biotherapeutics announced promising preclinical results for its next-generation Boltbody™ Immune-Stimulating Antibody Conjugates (ISACs) targeting CEACAM5 and PD-L1 at the AACR Annual Meeting [1][2] - The CEA-targeted ISAC demonstrated complete and durable anti-tumor responses in mice and was well-tolerated in non-human primates (NHPs) [2][5] - PD-L1 ISACs showed the ability to activate and reprogram PD-L1-expressing myeloid cells, promoting both innate and adaptive anti-tumor immunity [5][6] Group 1: CEA-targeted ISAC - The CEA ISAC is designed with a fully human antibody that specifically targets CEACAM5, commonly found in gastrointestinal cancers [2][4] - It enhances phagocytosis of CEA-positive tumor cells and stimulates the production of immune-activating cytokines such as IL-12p70, IFNg, and TNFa [2][5] - In a non-GLP NHP toxicity study, the CEA ISAC was well-tolerated at doses up to 15 mg/kg, with no significant drug-related adverse events observed [5] Group 2: PD-L1 ISAC - The PD-L1 ISAC utilizes a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist, targeting both tumor and immune cells expressing PD-L1 [3][5] - It has shown complete regressions and the induction of immunological memory in models resistant to PD-1/PD-L1 checkpoint inhibitors [5] - The efficacy of PD-L1 ISACs does not rely on the blockade of the PD-1/PD-L1 axis, suggesting a complementary mechanism to existing therapies [5] Group 3: Company Overview - Bolt Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for cancer treatment [7] - The company's pipeline includes BDC-3042, an agonist antibody targeting dectin-2, and BDC-4182, a next-generation Boltbody™ ISAC targeting claudin 18.2, with clinical trials expected to begin in Q2 2025 [7]

Châtillon, France, April 30, 2025   DBV Technologies Reports First Quarter 2025 Financial Results DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a clinical-stage biopharmaceutical company, today reported financial results for the First Quarter of 2025. The quarterly and three months financial statements were approved by the Board of Directors on April 30, 2025. Financial Highlights for the First Quarter Ended March 31, 2025 The Company’s interim conden ...

MDNA113 is a novel IL-13Rα2 tumor-targeted and “masked” anti-PD-1-IL-2 Superkine (anti-PD1-IL-2SK), engineered to precisely deliver clinically validated anti-PD1 and IL-2SK to the tumor microenvironment (TME) IL-13Rα2 is overexpressed by some of the most “immunologically cold” tumors with high unmet needs in pancreatic, liver, brain, breast, colon and prostate cancer that annually affect over 2 million patients worldwide MDNA113’s tumor targeting together with conditional activation provides a highly differ ...